Scope
Asthma + lung UK will invest between £3-5million to tackle breathlessness by accelerating the development of improved diagnostic approaches and robustly evidenced non-drug treatments.
The programme will focus on research that will address the needs of people who experience breathlessness, both those without a diagnosis and those living with a respiratory condition. While these groups are the primary focus, we expect the programme's outputs to deliver benefits that extend beyond respiratory health.
It will also align with the key themes of the Lung Research Grand Challenges: improving diagnosis, treatment and preventing attacks and exacerbations.
The information on this page is provided as guidance and as an introduction to this new research programme to allow collaborations to form. The full scope, eligibility, and application requirements will be published on our website in June 2027.
Focus
The programme will have the following focus:
A symptom focussed (and underlying condition-agnostic) approach to address the key priorities for breathlessness identified by patients, healthcare professionals and researchers by developing the following:
-
Non-drug treatments to reduce breathlessness
-
Better tools to assess and diagnose breathlessness
The following types of treatments, tools or products are not the focus of the programme:
-
Secondary/tertiary care-based interventions
-
NHS pathways
-
Drug treatments
Outcomes
Under each priority the following outcomes will be required:
-
Non-drug treatments to reduce breathlessness
While a small number of non-drug interventions exist, they are not available to the majority of people who experience breathlessness. The outcome of this priority will be the development of simple, low cost, effective, usable, accessible and desirable non-drug treatments to reduce breathlessness, available to all populations via either primary care or independent of the health system.
-
Tools to assess and diagnose breathlessness
Current tests are complicated and resource intensive, so they are only used in a minority of primary healthcare settings. The outcome of this priority will be the development of simple, non-invasive, inexpensive diagnostic and monitoring tools for both at home and primary care settings (tests should build on recent initiatives such as LifeArc and Asthma + Lung UK’s Diagnostic Target Product Profiles, and EPSRC’s funding of home and community-based respiratory health diagnostics [simple lung tests]) .
Research approach
The programme will take a centre-based approach where the principal applicant and host or grant-holding institution must be based in the UK.
Research approach:
-
A multi-disciplinary approach, including (but not limited to) product development, user-centred design, and economic assessment.
-
A clear pathway to adoption or commercialisation must be articulated (including estimated timescales) and collaboration with partners who can drive research outputs to adoption or commercialisation must be evidenced.
-
Products should aim to be market ready / achieve TRL9 within 5 years with:
-
Proven functionality (including providing the evidence for existing interventions and/or testing new interventions)
-
Tested with real users, with robust evidence of usage and effect on health inequalities (example methodology here: Fawkes et al. Co-designing the future of respiratory healthcare, CoDesign, 2025, 1-20.)
-
Clinically validated, compliant and deployable in routine care
-
Economic assessment of the product
-
Application process + information
This programme will open for applications in June 2027.
Please note that this information is for guidance only. Further details on funding scope, eligibility and application requirements will be published on our website in June 2027.
For any questions or for further information please contact Ian Jarrold by emailing research@asthmaandlung.org.uk.